Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


European Commission approves Veoza (fezolinetant) to treat vasomotor symptoms associated with menopause – Astellas

Written by | 18 Dec 2023 | Obstetrics & Gynaecology

Astellas Pharma Inc. announced the European Commission (EC) on December 7 approved Veoza (fezolinetant) 45 mg once daily for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. VMS, also known as hot flashes and/or night sweats, are common symptoms of menopause. Worldwide, more than half of women 40 to 64 years of age experience VMS, with rates in Europe ranging from 56% to 97%. The prevalence of moderate to severe VMS in postmenopausal women in Europe has been reported at 40%. VMS can have a disruptive impact on women’s daily activities and overall quality of life.

Prof. Rossella Nappi, Full Professor of Obstetrics and Gynecology, Chief of the Research Center for Reproductive Medicine and Director of the Gynecological Endocrinology & Menopause Unit, IRCCS San Matteo Foundation, University of Pavia. “I’ve been awaiting the marketing authorization of fezolinetant. I’m happy to see this advancement in women’s health and that my patients will soon have this new nonhormonal treatment option available to better control their moderate to severe VMS.”

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.